CYC
Director Trades
| Date | Director | Value |
|---|---|---|
| 25/2/25 | D. Heaney | $13,270 |
| 25/2/25 | J. Wigglesworth | $20,374 |
Company News
Cyclopharm granted maximum US market patent extension for Technegas imaging kit
Cyclopharm (ASX: CYC) has gained further momentum in its strategy to grow sales of its Technegas kit in the US after being granted an extension to its patent there. The new United States Patent and Trademark Office (USPTO) approval provides for the maximum patent term extension allowable of five years, covering the Technegas kit to […]
Cyclopharm secures major US deal to deploy Technegas products across HCA network
Radiopharmaceutical company Cyclopharm (ASX: CYC) has signed a contract to deploy its flagship product Technegas in as many as 169 nuclear medicine departments across the Hospital Corporation of America Healthcare (HCA) suite of facilities. The three-year contract marks a significant milestone for the company, as HCA operates one of the most comprehensive medical networks in […]
Diagnostic imaging: which stock will become the next Pro Medicus?
For all the leaps and bounds in medical science, the know-how behind detecting diseases hasn’t changed much in decades – or even centuries. Take X-rays, which are widely used despite the wee problem of irradiating the patients. And that’s because they are cheap and convenient. The underlying tech hasn’t really moved on since 1895, when […]
Cyclopharm set to take the fight against asthma to the next level via Technegas
Radiopharmaceutical company Cyclopharm (ASX: CYC) has received an operational boost with its flagship Technegas product named as the focus of a new clinical trial costing around A$387,000 seeking to develop better tools to diagnose and manage patients suffering from asthma and chronic obstructive pulmonary disease (COPD). The World Health Organisation (WHO) rates COPD as the […]